| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Platelet Activation | 54 | 2022 | 653 | 9.030 |
Why?
|
| Blood Platelets | 76 | 2023 | 2474 | 7.840 |
Why?
|
| Platelet Aggregation | 32 | 2022 | 806 | 3.700 |
Why?
|
| Platelet Function Tests | 26 | 2022 | 267 | 3.630 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 11 | 2018 | 350 | 3.400 |
Why?
|
| Platelet Aggregation Inhibitors | 39 | 2021 | 3014 | 3.320 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 24 | 2021 | 647 | 2.670 |
Why?
|
| Receptors, Purinergic P2Y12 | 12 | 2018 | 118 | 2.420 |
Why?
|
| Ticlopidine | 19 | 2018 | 883 | 2.330 |
Why?
|
| Dinucleoside Phosphates | 6 | 2018 | 73 | 2.320 |
Why?
|
| Adenosine Diphosphate | 18 | 2016 | 434 | 2.110 |
Why?
|
| P-Selectin | 20 | 2021 | 616 | 2.030 |
Why?
|
| Receptors, Purinergic P2Y1 | 7 | 2018 | 41 | 2.000 |
Why?
|
| Flow Cytometry | 29 | 2023 | 6093 | 2.000 |
Why?
|
| Platelet-Rich Plasma | 6 | 2021 | 174 | 1.880 |
Why?
|
| Hemostasis | 6 | 2023 | 450 | 1.700 |
Why?
|
| Thiophenes | 12 | 2018 | 601 | 1.680 |
Why?
|
| Purinergic P2 Receptor Antagonists | 5 | 2013 | 72 | 1.550 |
Why?
|
| Receptor, PAR-1 | 4 | 2021 | 114 | 1.500 |
Why?
|
| Platelet Count | 8 | 2021 | 795 | 1.480 |
Why?
|
| Blood Platelet Disorders | 5 | 2022 | 59 | 1.420 |
Why?
|
| Piperazines | 13 | 2013 | 2524 | 1.330 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 6 | 2020 | 140 | 1.190 |
Why?
|
| Aspirin | 16 | 2018 | 3190 | 1.180 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 5 | 2018 | 220 | 1.170 |
Why?
|
| Anemia, Sickle Cell | 8 | 2021 | 978 | 1.090 |
Why?
|
| Thrombasthenia | 6 | 2022 | 20 | 0.980 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 2 | 2013 | 34 | 0.920 |
Why?
|
| Integrin beta3 | 4 | 2018 | 119 | 0.850 |
Why?
|
| Immunoglobulin Fab Fragments | 8 | 2013 | 503 | 0.800 |
Why?
|
| Coronary Thrombosis | 4 | 2018 | 489 | 0.790 |
Why?
|
| Blood Coagulation | 11 | 2022 | 1110 | 0.780 |
Why?
|
| Thromboxane B2 | 4 | 2017 | 198 | 0.770 |
Why?
|
| Epidermal Growth Factor | 4 | 2021 | 723 | 0.770 |
Why?
|
| Electricity | 3 | 2021 | 176 | 0.750 |
Why?
|
| Platelet Membrane Glycoproteins | 16 | 2016 | 294 | 0.720 |
Why?
|
| Hematologic Agents | 1 | 2018 | 40 | 0.690 |
Why?
|
| Drug Resistance | 5 | 2009 | 1610 | 0.680 |
Why?
|
| Thrombocytopenia | 5 | 2021 | 1142 | 0.680 |
Why?
|
| Megakaryocytes | 2 | 2022 | 533 | 0.670 |
Why?
|
| Cyclooxygenase 1 | 2 | 2009 | 111 | 0.670 |
Why?
|
| Hemorrhage | 7 | 2021 | 3279 | 0.670 |
Why?
|
| Dog Diseases | 1 | 2018 | 135 | 0.660 |
Why?
|
| Thrombopoiesis | 1 | 2018 | 150 | 0.620 |
Why?
|
| Platelet Adhesiveness | 8 | 2016 | 160 | 0.610 |
Why?
|
| Immunophenotyping | 5 | 2022 | 1894 | 0.590 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2019 | 1743 | 0.580 |
Why?
|
| Cell-Derived Microparticles | 4 | 2021 | 165 | 0.550 |
Why?
|
| Acute Coronary Syndrome | 6 | 2018 | 2263 | 0.490 |
Why?
|
| Cytoplasmic Granules | 3 | 2022 | 618 | 0.470 |
Why?
|
| Adenosine | 2 | 2017 | 819 | 0.450 |
Why?
|
| CD40 Ligand | 7 | 2021 | 521 | 0.420 |
Why?
|
| Omeprazole | 1 | 2012 | 106 | 0.420 |
Why?
|
| Antibodies, Monoclonal | 21 | 2013 | 9548 | 0.410 |
Why?
|
| Thiazoles | 1 | 2018 | 1515 | 0.400 |
Why?
|
| Proton Pump Inhibitors | 2 | 2013 | 480 | 0.400 |
Why?
|
| Purinergic P2 Receptor Agonists | 1 | 2009 | 13 | 0.390 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 1252 | 0.390 |
Why?
|
| Liver Diseases | 1 | 2018 | 1243 | 0.380 |
Why?
|
| Receptors, Thrombin | 4 | 2022 | 137 | 0.380 |
Why?
|
| Leukocytes | 8 | 2016 | 2092 | 0.380 |
Why?
|
| Platelet-Derived Growth Factor | 4 | 2021 | 642 | 0.380 |
Why?
|
| Thrombin | 9 | 2021 | 605 | 0.370 |
Why?
|
| Humans | 121 | 2022 | 715777 | 0.350 |
Why?
|
| Communication | 2 | 2022 | 3516 | 0.340 |
Why?
|
| Clot Retraction | 1 | 2007 | 9 | 0.340 |
Why?
|
| Pyrazoles | 5 | 2019 | 1957 | 0.340 |
Why?
|
| Microfilament Proteins | 6 | 2017 | 1210 | 0.320 |
Why?
|
| Cardiology | 1 | 2018 | 1645 | 0.310 |
Why?
|
| Membrane Glycoproteins | 1 | 2018 | 3824 | 0.310 |
Why?
|
| Factor Va | 2 | 2021 | 10 | 0.310 |
Why?
|
| Dose-Response Relationship, Drug | 13 | 2018 | 11201 | 0.300 |
Why?
|
| Arachidonic Acid | 3 | 2006 | 435 | 0.290 |
Why?
|
| Coronary Artery Disease | 8 | 2016 | 6289 | 0.280 |
Why?
|
| Prodrugs | 1 | 2007 | 273 | 0.280 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 8 | 2021 | 3947 | 0.280 |
Why?
|
| Cross-Over Studies | 6 | 2017 | 2015 | 0.280 |
Why?
|
| Cell Adhesion Molecules | 7 | 2017 | 1659 | 0.280 |
Why?
|
| Fibrinogen | 7 | 2006 | 919 | 0.270 |
Why?
|
| Blood Coagulation Factors | 1 | 2007 | 369 | 0.270 |
Why?
|
| Serotonin | 2 | 2021 | 1032 | 0.260 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 4 | 2013 | 258 | 0.260 |
Why?
|
| Dogs | 7 | 2018 | 4046 | 0.250 |
Why?
|
| Double-Blind Method | 12 | 2019 | 11945 | 0.250 |
Why?
|
| Thrombelastography | 3 | 2018 | 158 | 0.250 |
Why?
|
| Cyclooxygenase 2 | 1 | 2006 | 630 | 0.240 |
Why?
|
| Peptides | 4 | 2013 | 4384 | 0.240 |
Why?
|
| Cardiovascular Diseases | 8 | 2015 | 14438 | 0.240 |
Why?
|
| Polymorphism, Genetic | 2 | 2017 | 4352 | 0.230 |
Why?
|
| Hydrazines | 2 | 2015 | 229 | 0.220 |
Why?
|
| Benzoates | 2 | 2015 | 238 | 0.220 |
Why?
|
| Tyrosine | 3 | 2003 | 1506 | 0.220 |
Why?
|
| Phosphoproteins | 5 | 2017 | 2538 | 0.220 |
Why?
|
| Annexin A5 | 2 | 2015 | 126 | 0.210 |
Why?
|
| Male | 57 | 2021 | 350324 | 0.210 |
Why?
|
| Female | 55 | 2021 | 377204 | 0.210 |
Why?
|
| Gaucher Disease | 1 | 2021 | 113 | 0.200 |
Why?
|
| Calgranulin A | 1 | 2021 | 79 | 0.200 |
Why?
|
| Calgranulin B | 1 | 2021 | 85 | 0.200 |
Why?
|
| Kinetics | 7 | 2017 | 6655 | 0.190 |
Why?
|
| Monocytes | 6 | 2015 | 2620 | 0.190 |
Why?
|
| Indicators and Reagents | 1 | 2021 | 477 | 0.190 |
Why?
|
| NFATC Transcription Factors | 1 | 2022 | 393 | 0.190 |
Why?
|
| Middle Aged | 40 | 2021 | 214639 | 0.180 |
Why?
|
| Electric Stimulation | 2 | 2015 | 1759 | 0.180 |
Why?
|
| Phenotype | 7 | 2023 | 16311 | 0.180 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2018 | 56 | 0.180 |
Why?
|
| Platelet Membrane Glycoprotein IIb | 1 | 2018 | 52 | 0.170 |
Why?
|
| Fibrinolytic Agents | 4 | 2016 | 2124 | 0.170 |
Why?
|
| Hypothermia, Induced | 1 | 2003 | 719 | 0.170 |
Why?
|
| Case-Control Studies | 10 | 2018 | 21797 | 0.170 |
Why?
|
| Cattle | 7 | 2019 | 3958 | 0.170 |
Why?
|
| Phosphatidylserines | 3 | 2021 | 184 | 0.170 |
Why?
|
| Coronary Restenosis | 1 | 2021 | 425 | 0.170 |
Why?
|
| Electrochemical Techniques | 1 | 2018 | 102 | 0.170 |
Why?
|
| Area Under Curve | 2 | 2013 | 1687 | 0.170 |
Why?
|
| Adenosine Monophosphate | 2 | 2017 | 271 | 0.160 |
Why?
|
| Hemophilia A | 1 | 2021 | 352 | 0.160 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2018 | 235 | 0.160 |
Why?
|
| Drug Interactions | 2 | 2013 | 1468 | 0.160 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2018 | 206 | 0.160 |
Why?
|
| Asphyxia | 1 | 2017 | 55 | 0.160 |
Why?
|
| Calpain | 1 | 2017 | 153 | 0.150 |
Why?
|
| Adult | 32 | 2021 | 212266 | 0.150 |
Why?
|
| Drug Therapy, Combination | 4 | 2019 | 6552 | 0.150 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2018 | 751 | 0.150 |
Why?
|
| Blood Specimen Collection | 2 | 2016 | 247 | 0.150 |
Why?
|
| Receptors, Purinergic P2X1 | 1 | 2015 | 8 | 0.150 |
Why?
|
| Pyrimidinones | 1 | 2018 | 373 | 0.150 |
Why?
|
| Purinergic P2X Receptor Antagonists | 1 | 2015 | 26 | 0.140 |
Why?
|
| Octoxynol | 1 | 2015 | 81 | 0.140 |
Why?
|
| Thrombosis | 5 | 2016 | 2843 | 0.140 |
Why?
|
| Gastroparesis | 1 | 2017 | 124 | 0.140 |
Why?
|
| Diabetic Nephropathies | 3 | 2019 | 1037 | 0.140 |
Why?
|
| Drug Stability | 1 | 2015 | 304 | 0.140 |
Why?
|
| Wiskott-Aldrich Syndrome | 1 | 2015 | 131 | 0.130 |
Why?
|
| Hemoglobins | 1 | 2021 | 1502 | 0.130 |
Why?
|
| Sudden Infant Death | 1 | 2017 | 283 | 0.130 |
Why?
|
| Cell Adhesion | 5 | 2003 | 3265 | 0.130 |
Why?
|
| Factor V | 2 | 2008 | 177 | 0.130 |
Why?
|
| Integrins | 4 | 1993 | 829 | 0.130 |
Why?
|
| Drug Administration Schedule | 3 | 2018 | 5031 | 0.130 |
Why?
|
| Collagen | 5 | 2009 | 2667 | 0.120 |
Why?
|
| Drug Monitoring | 3 | 2021 | 939 | 0.120 |
Why?
|
| Diabetic Neuropathies | 1 | 2017 | 419 | 0.120 |
Why?
|
| Scattering, Radiation | 1 | 2015 | 522 | 0.120 |
Why?
|
| Angioplasty, Balloon, Coronary | 6 | 2010 | 1866 | 0.120 |
Why?
|
| Stereoisomerism | 1 | 2014 | 638 | 0.120 |
Why?
|
| Aryldialkylphosphatase | 1 | 2013 | 65 | 0.120 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2013 | 1252 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2019 | 11090 | 0.110 |
Why?
|
| Time Factors | 9 | 2018 | 40875 | 0.110 |
Why?
|
| Methionine | 2 | 1986 | 611 | 0.110 |
Why?
|
| Consensus | 1 | 2021 | 2743 | 0.110 |
Why?
|
| Pain | 2 | 2021 | 4697 | 0.110 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2016 | 387 | 0.110 |
Why?
|
| Vascular Patency | 3 | 2009 | 841 | 0.110 |
Why?
|
| Treatment Outcome | 11 | 2019 | 62004 | 0.110 |
Why?
|
| Peptide Fragments | 7 | 2015 | 5111 | 0.110 |
Why?
|
| Reference Values | 2 | 2012 | 5050 | 0.110 |
Why?
|
| Young Adult | 13 | 2021 | 56226 | 0.110 |
Why?
|
| International Cooperation | 1 | 2018 | 1438 | 0.110 |
Why?
|
| Thromboxane A2 | 2 | 2008 | 114 | 0.100 |
Why?
|
| Chromatography, Liquid | 1 | 2015 | 961 | 0.100 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2015 | 372 | 0.100 |
Why?
|
| Platelet Activating Factor | 1 | 2011 | 156 | 0.100 |
Why?
|
| Cell Line | 3 | 2016 | 16576 | 0.100 |
Why?
|
| Structure-Activity Relationship | 2 | 2015 | 3206 | 0.100 |
Why?
|
| Light | 2 | 2015 | 1434 | 0.100 |
Why?
|
| Cell Proliferation | 3 | 2016 | 10620 | 0.100 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2013 | 209 | 0.100 |
Why?
|
| Monitoring, Physiologic | 1 | 2018 | 1755 | 0.100 |
Why?
|
| Neutrophils | 5 | 2022 | 3800 | 0.100 |
Why?
|
| Receptors, Purinergic P2X | 1 | 2009 | 6 | 0.100 |
Why?
|
| Adolescent | 11 | 2021 | 85155 | 0.100 |
Why?
|
| Serotonin 5-HT2 Receptor Antagonists | 1 | 2009 | 20 | 0.100 |
Why?
|
| Animals | 27 | 2022 | 169420 | 0.100 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2015 | 1402 | 0.090 |
Why?
|
| Drug Substitution | 1 | 2012 | 292 | 0.090 |
Why?
|
| Diabetic Angiopathies | 2 | 2016 | 845 | 0.090 |
Why?
|
| Aged | 18 | 2019 | 162448 | 0.090 |
Why?
|
| Serotonin Antagonists | 1 | 2009 | 149 | 0.090 |
Why?
|
| Parathyroid Hormone | 3 | 1986 | 1820 | 0.090 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2015 | 1119 | 0.090 |
Why?
|
| Thromboplastin | 2 | 2007 | 274 | 0.090 |
Why?
|
| Hydroxyurea | 2 | 2021 | 290 | 0.090 |
Why?
|
| Platelet Transfusion | 1 | 2011 | 285 | 0.080 |
Why?
|
| Receptors, Adenosine A2 | 1 | 2007 | 14 | 0.080 |
Why?
|
| Sepsis | 1 | 2022 | 2465 | 0.080 |
Why?
|
| Cell Separation | 2 | 2005 | 1817 | 0.080 |
Why?
|
| Biotransformation | 1 | 2007 | 162 | 0.080 |
Why?
|
| Predictive Value of Tests | 6 | 2015 | 15199 | 0.080 |
Why?
|
| Endothelium, Vascular | 2 | 2016 | 4586 | 0.080 |
Why?
|
| Cystic Fibrosis | 2 | 2007 | 1133 | 0.080 |
Why?
|
| ROC Curve | 1 | 2015 | 3524 | 0.080 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 19537 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2019 | 2930 | 0.080 |
Why?
|
| Cross-Sectional Studies | 3 | 2018 | 23438 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 3493 | 0.080 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 2 | 2007 | 404 | 0.080 |
Why?
|
| Receptors, Peptide | 1 | 1988 | 268 | 0.080 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2013 | 3294 | 0.080 |
Why?
|
| Myeloproliferative Disorders | 1 | 2013 | 604 | 0.080 |
Why?
|
| Calcium | 4 | 2021 | 5804 | 0.080 |
Why?
|
| Epitopes | 5 | 1992 | 2649 | 0.080 |
Why?
|
| Chest Pain | 1 | 2014 | 1109 | 0.080 |
Why?
|
| Ischemic Preconditioning, Myocardial | 1 | 2006 | 67 | 0.080 |
Why?
|
| Cell Differentiation | 2 | 2015 | 11655 | 0.070 |
Why?
|
| Morpholines | 1 | 2009 | 572 | 0.070 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2008 | 391 | 0.070 |
Why?
|
| Phosphorylation | 3 | 2013 | 8658 | 0.070 |
Why?
|
| Societies, Medical | 1 | 2018 | 3754 | 0.070 |
Why?
|
| Withholding Treatment | 1 | 2010 | 587 | 0.070 |
Why?
|
| Glycoproteins | 4 | 2002 | 2306 | 0.070 |
Why?
|
| Confidence Intervals | 1 | 2012 | 2993 | 0.070 |
Why?
|
| Oligopeptides | 5 | 1993 | 1236 | 0.070 |
Why?
|
| Dalteparin | 2 | 2003 | 42 | 0.070 |
Why?
|
| Receptors, Immunologic | 2 | 1989 | 1477 | 0.070 |
Why?
|
| Child, Preschool | 3 | 2018 | 41198 | 0.070 |
Why?
|
| Blood Cells | 1 | 2007 | 318 | 0.070 |
Why?
|
| Wound Healing | 1 | 2016 | 2778 | 0.070 |
Why?
|
| Cell Communication | 3 | 2022 | 1635 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2010 | 3375 | 0.070 |
Why?
|
| Antigens, Surface | 2 | 1986 | 1842 | 0.070 |
Why?
|
| Protein Conformation | 5 | 2001 | 4042 | 0.070 |
Why?
|
| Heterozygote | 2 | 2011 | 2794 | 0.060 |
Why?
|
| Anticoagulants | 2 | 2018 | 4375 | 0.060 |
Why?
|
| Benzamides | 1 | 2009 | 1390 | 0.060 |
Why?
|
| Coronary Angiography | 1 | 2015 | 4410 | 0.060 |
Why?
|
| Crotalid Venoms | 2 | 1993 | 34 | 0.060 |
Why?
|
| Binding, Competitive | 4 | 2001 | 1199 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2018 | 9030 | 0.060 |
Why?
|
| Tissue Fixation | 2 | 2001 | 256 | 0.060 |
Why?
|
| Genetic Variation | 2 | 2018 | 6664 | 0.060 |
Why?
|
| Laboratories | 1 | 2007 | 439 | 0.060 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2006 | 494 | 0.060 |
Why?
|
| Endothelium | 2 | 2003 | 802 | 0.060 |
Why?
|
| Epithelial Cells | 1 | 2015 | 3638 | 0.060 |
Why?
|
| Treatment Refusal | 1 | 2006 | 420 | 0.060 |
Why?
|
| Odds Ratio | 1 | 2015 | 9984 | 0.060 |
Why?
|
| Hematologic Neoplasms | 1 | 2013 | 1688 | 0.050 |
Why?
|
| Patient Compliance | 1 | 2013 | 2744 | 0.050 |
Why?
|
| Amino Acid Sequence | 11 | 1992 | 14161 | 0.050 |
Why?
|
| Gene Expression | 1 | 2015 | 7954 | 0.050 |
Why?
|
| Genotype | 5 | 2017 | 12919 | 0.050 |
Why?
|
| Image Cytometry | 1 | 2001 | 50 | 0.050 |
Why?
|
| Myocardial Infarction | 3 | 2009 | 11401 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2008 | 1726 | 0.050 |
Why?
|
| Infant | 3 | 2018 | 34569 | 0.050 |
Why?
|
| Antisickling Agents | 1 | 2021 | 78 | 0.050 |
Why?
|
| Signal Transduction | 3 | 2017 | 23729 | 0.050 |
Why?
|
| Child | 4 | 2018 | 74468 | 0.050 |
Why?
|
| Models, Cardiovascular | 1 | 2006 | 1002 | 0.050 |
Why?
|
| Comorbidity | 1 | 2015 | 10435 | 0.050 |
Why?
|
| Protein Binding | 3 | 2002 | 9559 | 0.050 |
Why?
|
| Hirudins | 1 | 2001 | 177 | 0.050 |
Why?
|
| Hydrogen Peroxide | 1 | 1984 | 725 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2013 | 3394 | 0.050 |
Why?
|
| Hemostatics | 1 | 2003 | 229 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 3741 | 0.050 |
Why?
|
| Hypertension | 1 | 2019 | 8270 | 0.050 |
Why?
|
| Blood Cell Count | 1 | 2021 | 418 | 0.050 |
Why?
|
| Coronary Disease | 3 | 2005 | 6150 | 0.050 |
Why?
|
| Circadian Rhythm | 1 | 2011 | 2554 | 0.050 |
Why?
|
| Disease Models, Animal | 6 | 2022 | 18199 | 0.050 |
Why?
|
| Expert Testimony | 1 | 2022 | 358 | 0.050 |
Why?
|
| Rats | 3 | 2015 | 24860 | 0.050 |
Why?
|
| Inflammation | 5 | 2022 | 10081 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2006 | 2054 | 0.040 |
Why?
|
| Point-of-Care Systems | 2 | 2016 | 1124 | 0.040 |
Why?
|
| Heparin | 3 | 2003 | 1620 | 0.040 |
Why?
|
| Factor VIII | 1 | 2021 | 346 | 0.040 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2011 | 1683 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 6722 | 0.040 |
Why?
|
| Recurrence | 2 | 2009 | 8240 | 0.040 |
Why?
|
| Angina, Unstable | 1 | 2003 | 929 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2017 | 1602 | 0.040 |
Why?
|
| Thrombolytic Therapy | 1 | 2007 | 2158 | 0.040 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 2017 | 90 | 0.040 |
Why?
|
| Epinephrine | 3 | 2008 | 809 | 0.040 |
Why?
|
| Calcitonin | 4 | 1980 | 352 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2002 | 1854 | 0.040 |
Why?
|
| Pharmacogenetics | 2 | 2012 | 699 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2007 | 4312 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 1525 | 0.040 |
Why?
|
| Actigraphy | 1 | 2021 | 452 | 0.040 |
Why?
|
| Risk Factors | 4 | 2018 | 70866 | 0.040 |
Why?
|
| Dosage Forms | 1 | 2017 | 57 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 1 | 2010 | 2548 | 0.040 |
Why?
|
| Ligands | 4 | 1991 | 3294 | 0.040 |
Why?
|
| Edetic Acid | 2 | 2004 | 282 | 0.040 |
Why?
|
| Prospective Studies | 5 | 2014 | 51315 | 0.040 |
Why?
|
| Binding Sites | 6 | 1993 | 6214 | 0.040 |
Why?
|
| E-Selectin | 1 | 2018 | 590 | 0.040 |
Why?
|
| Biological Availability | 1 | 2017 | 392 | 0.040 |
Why?
|
| Molecular Sequence Data | 9 | 1992 | 18591 | 0.040 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 2001 | 865 | 0.040 |
Why?
|
| Paresis | 1 | 2017 | 175 | 0.040 |
Why?
|
| Smoking | 2 | 2013 | 8980 | 0.040 |
Why?
|
| Cell Division | 2 | 2003 | 4699 | 0.030 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2017 | 325 | 0.030 |
Why?
|
| Equipment and Supplies | 1 | 1998 | 297 | 0.030 |
Why?
|
| Chromatography, Affinity | 3 | 1992 | 564 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2001 | 2034 | 0.030 |
Why?
|
| Heredity | 1 | 2015 | 164 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2014 | 7499 | 0.030 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2015 | 158 | 0.030 |
Why?
|
| Membrane Proteins | 3 | 2000 | 8047 | 0.030 |
Why?
|
| Carotid Artery Thrombosis | 1 | 1993 | 54 | 0.030 |
Why?
|
| Placebos | 1 | 2018 | 1735 | 0.030 |
Why?
|
| Fibrin | 1 | 2016 | 515 | 0.030 |
Why?
|
| Autopsy | 1 | 2017 | 988 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 2003 | 1216 | 0.030 |
Why?
|
| Exocytosis | 1 | 2015 | 362 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2019 | 8075 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2007 | 19910 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2017 | 1581 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 14902 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 12480 | 0.030 |
Why?
|
| Brain Stem | 1 | 2017 | 838 | 0.030 |
Why?
|
| Coronary Circulation | 2 | 2009 | 1652 | 0.030 |
Why?
|
| Chymotrypsin | 1 | 1991 | 152 | 0.030 |
Why?
|
| Erythroid Cells | 1 | 2013 | 250 | 0.030 |
Why?
|
| Bleeding Time | 1 | 2011 | 90 | 0.030 |
Why?
|
| Carbazoles | 1 | 2013 | 238 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 2016 | 1685 | 0.030 |
Why?
|
| United States | 1 | 2018 | 67905 | 0.020 |
Why?
|
| Cell Shape | 1 | 2011 | 375 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2001 | 4152 | 0.020 |
Why?
|
| Drug Inverse Agonism | 1 | 2009 | 6 | 0.020 |
Why?
|
| Janus Kinase 2 | 1 | 2013 | 516 | 0.020 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2009 | 76 | 0.020 |
Why?
|
| Hematocrit | 1 | 2011 | 637 | 0.020 |
Why?
|
| Cell Membrane | 5 | 2005 | 3879 | 0.020 |
Why?
|
| Oxidation-Reduction | 2 | 1986 | 2299 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2013 | 1660 | 0.020 |
Why?
|
| Blood Coagulation Tests | 1 | 1990 | 267 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2012 | 629 | 0.020 |
Why?
|
| Cations, Divalent | 1 | 1988 | 164 | 0.020 |
Why?
|
| Obesity | 1 | 2011 | 12248 | 0.020 |
Why?
|
| Temperature | 2 | 2011 | 2145 | 0.020 |
Why?
|
| Infant, Extremely Low Birth Weight | 1 | 2008 | 91 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 3 | 2013 | 6274 | 0.020 |
Why?
|
| Behavior | 1 | 2011 | 557 | 0.020 |
Why?
|
| Antigen-Antibody Complex | 1 | 1990 | 529 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 1821 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 15909 | 0.020 |
Why?
|
| Body Temperature | 1 | 2011 | 790 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2013 | 1255 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2012 | 814 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 1990 | 1171 | 0.020 |
Why?
|
| Extracellular Space | 2 | 1986 | 606 | 0.020 |
Why?
|
| Fibronectins | 1 | 1991 | 720 | 0.020 |
Why?
|
| Denmark | 1 | 2010 | 704 | 0.020 |
Why?
|
| Blood Coagulation Disorders | 1 | 1990 | 339 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2010 | 697 | 0.020 |
Why?
|
| Phenethylamines | 1 | 2007 | 104 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 2775 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2016 | 2151 | 0.020 |
Why?
|
| Mice | 3 | 2022 | 80375 | 0.020 |
Why?
|
| Homozygote | 1 | 2011 | 1856 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2014 | 1974 | 0.020 |
Why?
|
| Methanol | 1 | 1986 | 90 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2007 | 2280 | 0.020 |
Why?
|
| Cell Aggregation | 1 | 2005 | 255 | 0.020 |
Why?
|
| Alprostadil | 1 | 2005 | 87 | 0.020 |
Why?
|
| Destrin | 1 | 2004 | 13 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 13643 | 0.020 |
Why?
|
| Cysteamine | 1 | 1984 | 23 | 0.020 |
Why?
|
| Cardiovascular System | 1 | 2011 | 763 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 2950 | 0.020 |
Why?
|
| Cyanogen Bromide | 1 | 1984 | 84 | 0.020 |
Why?
|
| Cytoplasm | 2 | 1986 | 1625 | 0.020 |
Why?
|
| Macrophage-1 Antigen | 1 | 2005 | 295 | 0.020 |
Why?
|
| Cytochalasin D | 1 | 2004 | 99 | 0.020 |
Why?
|
| Factor Xa | 1 | 2005 | 162 | 0.020 |
Why?
|
| Chick Embryo | 1 | 1986 | 971 | 0.020 |
Why?
|
| Actin Depolymerizing Factors | 1 | 2004 | 51 | 0.020 |
Why?
|
| Insulin | 1 | 2019 | 6651 | 0.020 |
Why?
|
| Amino Acids | 2 | 1992 | 1711 | 0.020 |
Why?
|
| Alleles | 2 | 2013 | 7099 | 0.020 |
Why?
|
| Polysomnography | 1 | 2011 | 1710 | 0.020 |
Why?
|
| Blotting, Western | 3 | 2005 | 5379 | 0.020 |
Why?
|
| Fetal Blood | 1 | 2011 | 1324 | 0.020 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2004 | 117 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 3542 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2016 | 8545 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2013 | 2594 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2013 | 2515 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2016 | 3374 | 0.020 |
Why?
|
| Ibuprofen | 1 | 2005 | 244 | 0.010 |
Why?
|
| Infant, Newborn | 3 | 2011 | 24798 | 0.010 |
Why?
|
| Methods | 1 | 2003 | 1160 | 0.010 |
Why?
|
| Species Specificity | 1 | 2007 | 2599 | 0.010 |
Why?
|
| Chelating Agents | 1 | 2004 | 401 | 0.010 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2013 | 1592 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 2006 | 1438 | 0.010 |
Why?
|
| Solubility | 1 | 2004 | 1136 | 0.010 |
Why?
|
| Atherectomy | 1 | 2001 | 44 | 0.010 |
Why?
|
| Dipeptides | 1 | 2004 | 409 | 0.010 |
Why?
|
| Glomerular Filtration Rate | 1 | 2010 | 2103 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2017 | 15059 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2012 | 9596 | 0.010 |
Why?
|
| Kidney Cortex | 1 | 1981 | 185 | 0.010 |
Why?
|
| Random Allocation | 1 | 2006 | 2445 | 0.010 |
Why?
|
| Kidney | 2 | 2010 | 6881 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2014 | 39300 | 0.010 |
Why?
|
| Matrix Metalloproteinases | 1 | 2004 | 402 | 0.010 |
Why?
|
| Platelet Storage Pool Deficiency | 1 | 2000 | 4 | 0.010 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2001 | 221 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1986 | 2599 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 2005 | 1505 | 0.010 |
Why?
|
| Blood | 1 | 2003 | 617 | 0.010 |
Why?
|
| Vitamin E | 1 | 2005 | 856 | 0.010 |
Why?
|
| Antibodies, Blocking | 1 | 2001 | 261 | 0.010 |
Why?
|
| Protease Inhibitors | 1 | 2004 | 784 | 0.010 |
Why?
|
| Saphenous Vein | 1 | 2003 | 512 | 0.010 |
Why?
|
| Blood Banks | 1 | 2000 | 106 | 0.010 |
Why?
|
| Genome, Human | 1 | 2013 | 4471 | 0.010 |
Why?
|
| Creatine Kinase | 1 | 2001 | 707 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2009 | 4214 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2021 | 23464 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 22665 | 0.010 |
Why?
|
| Models, Biological | 1 | 2016 | 9809 | 0.010 |
Why?
|
| Syndrome | 1 | 2004 | 3193 | 0.010 |
Why?
|
| Endopeptidases | 1 | 1981 | 779 | 0.010 |
Why?
|
| Calibration | 1 | 2000 | 797 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 2292 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1984 | 3818 | 0.010 |
Why?
|
| Quality Control | 1 | 2000 | 867 | 0.010 |
Why?
|
| Specimen Handling | 1 | 2002 | 698 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 4893 | 0.010 |
Why?
|
| Fatty Acids | 1 | 2005 | 1746 | 0.010 |
Why?
|
| Apoptosis | 1 | 2013 | 9973 | 0.010 |
Why?
|
| Mutation | 2 | 1992 | 29291 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2001 | 1803 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2011 | 4164 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2001 | 1928 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2011 | 8544 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2007 | 8890 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1979 | 2124 | 0.010 |
Why?
|
| Coronary Vessels | 1 | 2006 | 2977 | 0.010 |
Why?
|
| Survival Rate | 1 | 2010 | 13206 | 0.010 |
Why?
|
| Exercise | 1 | 2011 | 5427 | 0.010 |
Why?
|
| Radioimmunoassay | 3 | 1980 | 956 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2017 | 40029 | 0.010 |
Why?
|
| Acute Disease | 1 | 2005 | 7140 | 0.010 |
Why?
|
| Base Sequence | 3 | 1992 | 13179 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2011 | 12535 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 17409 | 0.010 |
Why?
|
| Disease Progression | 1 | 2010 | 13215 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 4455 | 0.010 |
Why?
|
| Prognosis | 1 | 2013 | 29005 | 0.010 |
Why?
|
| Recombinant Proteins | 2 | 1992 | 6803 | 0.010 |
Why?
|
| Age Factors | 1 | 2008 | 18784 | 0.010 |
Why?
|
| Hydrolysis | 1 | 1991 | 684 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1990 | 428 | 0.010 |
Why?
|
| Vitronectin | 1 | 1989 | 47 | 0.010 |
Why?
|
| Receptors, Vitronectin | 1 | 1989 | 55 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 13213 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1990 | 1119 | 0.010 |
Why?
|
| CHO Cells | 1 | 1992 | 1437 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 11689 | 0.010 |
Why?
|
| Primary Myelofibrosis | 1 | 1990 | 197 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1991 | 1890 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1992 | 1778 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1989 | 892 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1993 | 2647 | 0.010 |
Why?
|
| Aspartic Acid | 1 | 1990 | 579 | 0.010 |
Why?
|
| Cricetinae | 1 | 1992 | 2589 | 0.010 |
Why?
|